Abbvie Inc (ABBV)

$221.59 -6.14 (-2.70%)
Market Cap 402.35B
Revenue (ttm) 61.16B
Net Income (ttm) 4.23B
EPS (ttm) N/A
PE Ratio 22.06
Forward PE 15.72
Profit Margin 6.91%
Debt to Equity Ratio -11.02
Volume 5,261,900
Avg Vol 6,011,024
Day's Range N/A - N/A
Shares Out 1.77B
Stochastic %K 87%
Beta 0.32
Analysts Strong Sell
Price Target $251.55

Company Profile

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides...

Industry: Drug Manufacturers - General
Sector: Healthcare
Phone: 847 932 7900
Address:
1 North Waukegan Road, North Chicago, United States
MRTunity
MRTunity Jun. 16 at 4:06 PM
$SLS This months MAIN EVENT Wrestlemania Style… in the biotech sphere 🧬 💪 Tag team Championship belt on the line for GPS+SLS009… We got in one corner $RHHBY & $ABBV In the other corner team of $MRK & $PFE Who you places your bets on Longs ⁉️ Mine is on SELLAS LIFE SCIENCES + Angelos 👊🏼
2 · Reply
TeamSetupAlpha
TeamSetupAlpha Jun. 16 at 3:15 PM
When that big pullback happened after our historic run-up, retail was panicking about a "double top" failure. But inside our small trading circle, we called it for what it was: a healthy retest of previous resistance turned support. We didn’t short; we aggressively re-entered at the exact bottom of that June dip. Boom. Up 132% YTD today. Stop trading alone in the dark. $PG $TMO $LIN $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 16 at 1:16 PM
$SLS $GILD $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 16 at 1:11 PM
$SLS "very soon" Everyone Understands why the SLS Share Price Jumped everytime they announced another Event Milestone! The IDMC Unblinded ACTUAL Phase 3 Survival and Immune Response Data from the Interim Analysis at 60 Events... Actual P3 DATA ... from the ongoing trial - that told all the INDUSTRY Players $ABBV $RHHBY $BMY who Own the BAT / Aza VEN - Gps is GOLDEN. They Know Aza+VEN Just Failed 3 Large Phase 3 AML Trials, including Failing the VIALE-M AML Maintenance Remission Trial (CR1). Aza+VEN Failed the First Remission Patients in Viale-M - just like it Failed the REGAL Phase 3 CONTROL ARM Patients in Second Remission (CR2).
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 16 at 12:25 PM
$SLS $GILD $ABBV https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won
0 · Reply
focafoca99
focafoca99 Jun. 16 at 12:10 PM
$ABBV receives FDA approval for SKINVIVE by JUVÉDERM to treat neck lines. https://www.rapidticker.com/news/abbv-allergan-aesthetics-receives-us-fda-7e0c95
0 · Reply
cubie
cubie Jun. 16 at 12:45 AM
$IRWD $ABBV $ALIT $SPCX $CNXC u should've sold all lol😆
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 15 at 7:02 PM
$SLS $GILD $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 15 at 4:28 PM
$SLS $ABVX SLS is about to announce the 80th and Final Event ... Not the trial results, just the 80th event, the share Price will launch. ... ahead of the Phase 3 Result, which is about 40x more valuable than the current share price. The 80th Event Puts a $28B TAM - $40B of Value on the Table. - Ballistic Verticality incoming. THE 80th EVENT PR is a A SURE THING WINNER - massive Catalyst to be Followed by an even more massive catalyst -Final Phase 3 Registrational Results Giving Gps the FDA Green Light to Generate Tens of Billions of Dollars - Tens of Billions in Real Revenue worth $40B to $LLY $ABBV - this $1.5B Manipulated Equity is worth $40B the Instant P3 Data Hits.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 15 at 3:37 PM
$SLS $ABBV $SLS Announced the 60th Event, the share price Launched - because the IDMC Unblinded actual MOS and IR Data from the Interim Analysis - told all industry participants Gps works. *** SLS Announced the 72nd Event, the share price Launched SLS Announced the 78th Event, the share price Launched SLS is about to announce the 80th and Final Event ... Not the trial results, just the 80th event, the share Price will launch ahead of the Phase 3 Result, which is about 40x more valuable than the current share price. The 80th Event Puts a $28B TAM - $40B of Value on the Table. - Ballistic Verticality incoming. THE 80th EVENT PR is a A SURE THING WINNER - massive Catalyst to be Followed by an even more massive catalyst-Final Results Giving Gps the FDA Green Light to Generate Tens of Billions of Dollars - Tens of Billions in Real Revenue worth $40B to $LLY $ABBV - this $1.5B Manipulated Equity is worth $40B the Instant P3 Data Hits
0 · Reply
Latest News on ABBV
No data available.
MRTunity
MRTunity Jun. 16 at 4:06 PM
$SLS This months MAIN EVENT Wrestlemania Style… in the biotech sphere 🧬 💪 Tag team Championship belt on the line for GPS+SLS009… We got in one corner $RHHBY & $ABBV In the other corner team of $MRK & $PFE Who you places your bets on Longs ⁉️ Mine is on SELLAS LIFE SCIENCES + Angelos 👊🏼
2 · Reply
TeamSetupAlpha
TeamSetupAlpha Jun. 16 at 3:15 PM
When that big pullback happened after our historic run-up, retail was panicking about a "double top" failure. But inside our small trading circle, we called it for what it was: a healthy retest of previous resistance turned support. We didn’t short; we aggressively re-entered at the exact bottom of that June dip. Boom. Up 132% YTD today. Stop trading alone in the dark. $PG $TMO $LIN $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 16 at 1:16 PM
$SLS $GILD $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 16 at 1:11 PM
$SLS "very soon" Everyone Understands why the SLS Share Price Jumped everytime they announced another Event Milestone! The IDMC Unblinded ACTUAL Phase 3 Survival and Immune Response Data from the Interim Analysis at 60 Events... Actual P3 DATA ... from the ongoing trial - that told all the INDUSTRY Players $ABBV $RHHBY $BMY who Own the BAT / Aza VEN - Gps is GOLDEN. They Know Aza+VEN Just Failed 3 Large Phase 3 AML Trials, including Failing the VIALE-M AML Maintenance Remission Trial (CR1). Aza+VEN Failed the First Remission Patients in Viale-M - just like it Failed the REGAL Phase 3 CONTROL ARM Patients in Second Remission (CR2).
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 16 at 12:25 PM
$SLS $GILD $ABBV https://www.fiercepharma.com/pharma/inside-abbvies-10b-immunogen-buyout-and-bidding-war-it-won
0 · Reply
focafoca99
focafoca99 Jun. 16 at 12:10 PM
$ABBV receives FDA approval for SKINVIVE by JUVÉDERM to treat neck lines. https://www.rapidticker.com/news/abbv-allergan-aesthetics-receives-us-fda-7e0c95
0 · Reply
cubie
cubie Jun. 16 at 12:45 AM
$IRWD $ABBV $ALIT $SPCX $CNXC u should've sold all lol😆
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 15 at 7:02 PM
$SLS $GILD $ABBV
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 15 at 4:28 PM
$SLS $ABVX SLS is about to announce the 80th and Final Event ... Not the trial results, just the 80th event, the share Price will launch. ... ahead of the Phase 3 Result, which is about 40x more valuable than the current share price. The 80th Event Puts a $28B TAM - $40B of Value on the Table. - Ballistic Verticality incoming. THE 80th EVENT PR is a A SURE THING WINNER - massive Catalyst to be Followed by an even more massive catalyst -Final Phase 3 Registrational Results Giving Gps the FDA Green Light to Generate Tens of Billions of Dollars - Tens of Billions in Real Revenue worth $40B to $LLY $ABBV - this $1.5B Manipulated Equity is worth $40B the Instant P3 Data Hits.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 15 at 3:37 PM
$SLS $ABBV $SLS Announced the 60th Event, the share price Launched - because the IDMC Unblinded actual MOS and IR Data from the Interim Analysis - told all industry participants Gps works. *** SLS Announced the 72nd Event, the share price Launched SLS Announced the 78th Event, the share price Launched SLS is about to announce the 80th and Final Event ... Not the trial results, just the 80th event, the share Price will launch ahead of the Phase 3 Result, which is about 40x more valuable than the current share price. The 80th Event Puts a $28B TAM - $40B of Value on the Table. - Ballistic Verticality incoming. THE 80th EVENT PR is a A SURE THING WINNER - massive Catalyst to be Followed by an even more massive catalyst-Final Results Giving Gps the FDA Green Light to Generate Tens of Billions of Dollars - Tens of Billions in Real Revenue worth $40B to $LLY $ABBV - this $1.5B Manipulated Equity is worth $40B the Instant P3 Data Hits
0 · Reply
officialshawn
officialshawn Jun. 15 at 1:48 PM
$SMMT Bob posted a video on his instagram about his recent $50,000,000 purchase. He is getting close to a billion invested and I think he will will probably be there soon. $PLSE $ISRG $ABBV
1 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 15 at 6:37 AM
$SLS $ABBV
0 · Reply
AdamBrennan2
AdamBrennan2 Jun. 15 at 2:01 AM
$LLY pricing in 16.6% free cash flow growth, i think the growth will be much more than this with reta $NVO $JNJ $ABBV $NVS
0 · Reply
Crestedgetrade
Crestedgetrade Jun. 14 at 11:52 PM
06/15/2026 WATCHLIST 🎶 Inside Bar (D): $ABBV 🩺 — watching key breakout above 228.58 / breakdown below 221.17 $WMT 🏬 — reaction zone 121.86 / 119.46 Gap / Momentum Watch (D): $HOOD📱 — breakout level 96.10 $TGT 🎯— breakout level 136.26 Market still reacting to levels, no bias, just price action. 📈📉 Drop a ❤️ if you’re watching these setups.
0 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 14 at 10:05 PM
$SLS Aza+VEN, BAT for Control Arm Patients in the REGAL Phase 3 AML Second Remission CR2 Maintenance Trial, Recently FAILED, 3 Large Phase 3 Trials Conducted by $ABBV Including Failing the VIALE-M - AML CR1 Remission Maintenance Trial. BAT / Aza+VEN has Failed the REGAL CR2 Remission Patients as well. it is not complicated. Dr's Jamy Levy and Tsirigotis are all On Record - BAT is Toxic, survival is Dismal, Not Durable - Extremely Poor.
0 · Reply
dewmoore
dewmoore Jun. 14 at 3:28 PM
$LLY Oncology Head confirmed they have a pile of cash & ZERO arbitrary limits on deal size for de-risked assets with solid human data. If the science delivers, they want in. Cash is NO problem! BOOM! Which brings us back to this: Stop calling for a "2-week lag" after the 80th event. $SLS 8-K calendar blueprint proves otherwise: • Dec '25: Cut-off Fri 12/26 > 8-K Mon 12/29 (1 biz day!) • May '26: Cut-off Mon 5/11 > 8-K Tue 5/12 (24-hr turnaround!) The old lag is DEAD! Continuous CRO scrubbing & AI-driven capture mean validation takes HOURS. Zero May deaths is mathematically impossible for late-stage AML. Following the 23-day cadence, the 79th hit mid-May, putting the 80th right now—on pace for a late June/early July announcement. With a tiny ~196M share count, a $10.5B GSK-style buyout puts the stock at $53.40. Factor in the full WT1 platform/SLS-009 at $20B shares hit $101.71+ before pricing in the massive short squeeze and scrambling funds. $PFE $MRK $ABBV https://www.youtube.com/watch?v=t93lYkzLQMU&t=481s
1 · Reply
Dopamineaddict
Dopamineaddict Jun. 14 at 1:05 PM
$ANVS The new Nature Medicine paper on the "Aβ-tau inflection point" reveals a massive 2-step therapeutic roadmap for oral CNS assets like buntanetap. The study maps a critical tipping point: early AD is driven by Aβ accumulation, which eventually shifts into a late-stage, destructive microglial immune response driving tau pathology and cell death. This provides a clear clinical division of labor: Buntanetap for Mild AD: By cutting off upstream translation of neurotoxic proteins (Aβ/Tau), $ANVS is perfectly positioned to stop the initial triggers before the brain crosses this dangerous inflection point. Masitinib (AB Science, located in France) for Progressed AD: Once the tipping point is crossed, the raging neuroinflammatory fire takes over. Masitinib's c-Kit/LYN microglial modulation is needed to directly target that hyper-activated late-stage immune response. $LLY $BIIB $ABBV
4 · Reply
55X_ROI_Q1_2026
55X_ROI_Q1_2026 Jun. 13 at 7:12 PM
$SLS Does Everyone Understand Aza+VEN / BAT / Best Available Treatment for REGAL PH3 Control Arm Patients - Recently FAILED 3 Large Phase 3 Trials conducted by $ABBV - including this CR1 trial??? A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy (VIALE-M) clinicaltrials.gov:443/ ID NCT04102020 Sponsor AbbVie Information provided by AbbVie (Responsible Party) Last Update Posted 2026-04-08 https://clinicaltrials.gov/study/NCT04102020?term=viale-M&viewType=Card&rank=1
0 · Reply
John_Wick1234
John_Wick1234 Jun. 13 at 11:17 AM
$ABBV Rounding Bottom with good volume.
0 · Reply
topstockalerts
topstockalerts Jun. 12 at 8:47 PM
Leerink reported a rebound in U.S. prescription trends for the week ended June 5, 2025, with the overall pharmaceutical market growing 10% week-over-week after an 8% decline during the Memorial Day period. Eli Lilly's tirzepatide franchise (Mounjaro/Zepbound) posted prescription growth of 46% year-over-year over one week, 51% over four weeks, and 57% over 12 weeks. Novo Nordisk's semaglutide products (Ozempic/Wegovy) recorded growth of 22%, 21%, and 18%, respectively. Wegovy prescriptions rose 10% week-over-week, while Zepbound increased 9%. Foundayo generated roughly 20,000 prescriptions in its ninth week on the market, up 17% sequentially but still well below oral Wegovy's approximately 81,000 prescriptions during its ninth week. Oral Wegovy reached around 159,000 prescriptions in its 22nd launch week, although Leerink noted IQVIA data likely understates demand by excluding certain direct-to-consumer channels. $LLY $NVO $ABBV $JNJ
0 · Reply
maphere
maphere Jun. 12 at 4:25 PM
$RGNX $ABBV Try this again. High profiled clinical investigative site, Bay Area Retina, added the DR trial although not yet listed on clinical trials. gov site. Check out the notes (minutes) for approval that were generated April 26l listed to the RIGHT of the trial listing. https://www.bayarearetina.com/clinical-trials
1 · Reply
AlphaFoundry
AlphaFoundry Jun. 12 at 3:33 PM
$ABBV 's new immunology pipeline perfectly offsets the Humira cliff. While $BABA 's buyback is aggressive, fierce domestic e-commerce competition keeps the stock grinding at the bottom.
0 · Reply